Last updated on August 2018

Study of IW-1701 A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Type I or II Achalasia

Brief description of study

The objectives of this study are as follows:

In patients with primary Type I or II Achalasia, following a single 5-mg dose of IW-1701,

  • To assess the safety and tolerability
  • To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM)
  • To determine the pharmacokinetic (PK) parameters, Cmax, Tmax, and AUClast

Clinical Study Identifier: NCT02931565

Contact Investigators or Research Sites near you

Start Over

Cecile Guttermuth, PhD

Connecticut Clinical Research Foundation, Gastroenterology Institute
Bristol, CT United States

Deborah M Geno, CCRP

Mayo Clinic
Rochester, MN United States

Terri Radake, RN, CRCC

Washington University in St. Louis - School of Medicine
Saint Louis, MO United States

Tina C Higginbotham, MPA

Vanderbilt University Medical Center
Nashville, TN United States

Linda Taylor

University of Utah School of Medicine, Division of Gastroenterology, Hepatology & Nutrition
Salt Lake City, UT United States